Elephants, Parkinson's Disease, and Proof‐of‐Concept Clinical Trials
2018; Wiley; Volume: 33; Issue: 5 Linguagem: Inglês
10.1002/mds.27398
ISSN1531-8257
Autores Tópico(s)Nuclear Receptors and Signaling
ResumoMovement DisordersVolume 33, Issue 5 p. 697-700 Viewpoint Elephants, Parkinson's Disease, and Proof-of-Concept Clinical Trials Jesse M. Cedarbaum MD, Corresponding Author Jesse M. Cedarbaum MD jesse.cedarbaum@biogen.com Biogen, Cambridge, Massachusetts, USACorrespondence to: Jesse M. Cedarbaum, MD, Biogen, Research and Early Development, 300 Binney St., Cambridge, MA 02142; jesse.cedarbaum@biogen.comSearch for more papers by this author Jesse M. Cedarbaum MD, Corresponding Author Jesse M. Cedarbaum MD jesse.cedarbaum@biogen.com Biogen, Cambridge, Massachusetts, USACorrespondence to: Jesse M. Cedarbaum, MD, Biogen, Research and Early Development, 300 Binney St., Cambridge, MA 02142; jesse.cedarbaum@biogen.comSearch for more papers by this author First published: 03 May 2018 https://doi.org/10.1002/mds.27398Citations: 7 Relevant conflicts of interest/financial disclosures: : Author is full-time employee and shareholder in Biogen. Funding agencies: : Biogen MA Inc. Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat Citing Literature Volume33, Issue5May 2018Pages 697-700 RelatedInformation
Referência(s)